Introduction
============

Glucocorticoids exert pleiotrophic effects on metabolism and energy partitioning. Centrally, they increase food intake and reduce energy expenditure, whilst peripherally, they promote insulin resistance, fat accumulation ([@bib7], [@bib23]) and hypertension ([@bib46], [@bib56]). Polymorphisms in the human glucocorticoid receptor *NR3c1* gene (GR) are associated with glucocorticoid hypersensitivity, visceral obesity, hypertension and increased cardiovascular disease risk ([@bib2], [@bib44], [@bib9], [@bib50],[@bib51], [@bib53]). Many rodent models of obesity are characterised by hypercorticosteronaemia, with weight gain normalised following adrenalectomy and reinstated by glucocorticoid replacement ([@bib8], [@bib12], [@bib45], [@bib28]). Although plasma glucocorticoid levels are normal in human idiopathic obesity ([@bib11]), it has been proposed that intra-adipose glucocorticoid action is selectively increased, through increased adipose expression of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), the intracellular enzyme that regenerates active glucocorticoids from intrinsically inert 11-keto-glucocorticoids ([@bib24], [@bib20], [@bib1]).

Obese humans ([@bib41], [@bib38], [@bib26], [@bib22]) and some rodent models of obesity ([@bib27], [@bib29]) have selectively increased adipose levels of 11β-HSD1 and transgenic overexpression of 11β-HSD1 in adipocytes causes hyperphagia, obesity, insulin resistance and hypertension despite unchanged systemic glucocorticoid levels ([@bib29], [@bib30]). Hepatic overexpression of 11β-HSD1 has no effect on adiposity, but causes hypertension and insulin resistance ([@bib37]). Conversely, mice deficient in 11β-HSD1 are insulin sensitised and resist the adverse metabolic effects of a high-fat diet ([@bib24], [@bib32], [@bib33]).

Proopiomelanocortin (POMC) is a polypeptide precursor which undergoes extensive post-translational modification to yield a range of smaller, biological active peptides. These include α-, β- and γ-melanocyte-stimulating hormone and adrenocorticotrophic hormone (ACTH), collectively known as melanocortins. Inactivating mutations of the *POMC* gene in humans and mice result in a complex phenotype. Loss of melanocortin signalling within the hypothalamus causes hyperphagia and obesity ([@bib25], [@bib57], [@bib4]). Further, a failure to produce ACTH within the anterior pituitary causes adrenal insufficiency with low or absent circulating glucocorticoids ([@bib25], [@bib57], [@bib4]). *Pomc*^*−/−*^ mice are therefore unusual amongst rodent models in that obesity develops in the absence of circulating glucocorticoids. However, glucocorticoid treatment exacerbates hyperphagia and obesity in adult *Pomc*^*−/−*^ mice and induces severe insulin resistance, hyperleptinaemia and diabetes ([@bib6]).

We have tested the hypothesis that increased glucocorticoid action in peripheral tissues of glucocorticoid-treated *Pomc*^*−/−*^ mice contributes to their apparent glucocorticoid hypersensitivity and exaggerated metabolic syndrome-like phenotype. We further demonstrate that glucocorticoid replacement induces hypertension in *Pomc*^*−/−*^ mice, independently of renin--angiotensin system (RAS) activation.

Materials and Methods
=====================

Animals and CORT replacement
----------------------------

The generation of *Pomc*^*−/−*^ mice on a 129/SvEv background has been described previously ([@bib4]). All mice were housed in standard conditions on a 12 h light:12 h darkness cycle (lights on 0070 h) with *ad libitum* access to water and chow (4·5% fat diet, Special Diet Services, Witham, UK). Eight-week-old male mice (*n*=5 per group) were treated with corticosterone (25 μg/ml) in their drinking water, a dose that results in similar plasma glucocorticoid levels and hypothalamic corticotrophin releasing hormone (CRH) mRNA levels in *Pomc*^*−/−*^ and wild-type mice ([@bib6]). All animal protocols used in these studies were approved under the auspices of the UK Home Office Animals (Scientific Procedures) Act 1986.

Blood pressure measurement
--------------------------

Systolic blood pressure was measured photoelectrically in the tail of restrained conscious mice using an IITC model 179 analyser (Woodland Hills, CA, USA). Prior to recording measurements, all mice underwent three periods of training to accustom them to the procedure. Mice were warmed at 32 °C for 30 min before taking ten consecutive readings. The first five were discounted and a mean value of systolic blood pressure was calculated from the last five readings. Five mice from each treatment group were measured. All analogue recordings were analysed by an independent observer who was blinded to the genotype of the mice and any treatment they had received.

Plasma hormone and lipid measurements
-------------------------------------

Animals were killed between 0800 and 0900 h by cervical dislocation. Trunk blood samples were collected into EDTA-coated tubes (Sarstedt, Leicester, UK), centrifuged at 6000 ***g*** for 10 min and plasma stored at −80 °C until required for assay. Non-esterified fatty acid (NEFA) and triglyceride levels were determined by commercial kits (NEFA, Roche Diagnostics; triglyceride, Dade Behring, Marburg, Germany). Plasma renin and angiotensinogen concentrations were determined as previously described ([@bib31]).

Tissue morphology and hepatic triglyceride levels
-------------------------------------------------

Neutral lipids, cholesterol and fatty acids were identified by light microscopy at 40× magnification in cryostat liver sections (30 μm) stained with oil red O (Sigma) and counter stained with haematoxylin as previously described ([@bib31]). Hepatic triglycerides were extracted by homogenisation in isopropanol (ten volumes) and then incubated at 37 °C for 45 min and measured spectrophotometrically in supernatants (3000 ***g*** for 10 min) using reagent TR224221 (Alpha Laboratories, Eastleigh, Hampshire, UK).

RNA extraction and northern blot analysis
-----------------------------------------

Pieces of liver and adipose tissues (inguinal, retroperitoneal and epididymal) were rapidly frozen in dry ice, stored at −80 °C and then homogenised in Trizol reagent (Invitrogen). Total RNA was purified using a binding matrix (RNaid Plus kit, BIO 101; Anachem, UK) and eluted in diethylpyrocarbonate-treated water containing 400 U/ml RNasin (Promega) and 10 mmol/l dithiothreitol. RNA (5--10 μg) was blotted and hybridised to ^32^P-labelled cDNA probes for mouse 11β-HSD1, GR, angiotensinogen, phosphoenolpyruvate carboxykinase (PEPCK), lipoprotein lipase (LPL) and 18S as previously described ([@bib31]). Specific mRNAs were quantified using a phosphorimager (Fuji BAS FLA 2000, Raytek, Sheffield, UK) and Aida image analysis software (Raytek) and are expressed in arbitrary units relative to 18S RNA.

Statistical analyses
--------------------

The effects of genotype and corticosterone interactions were assessed by two-way ANOVA followed by *post hoc* Tukey\'s tests for group differences. Significance was set at *P*\<0·05. Values are means±[s.e.m]{.smallcaps}.

Results
=======

*Pomc*^*−/−*^ mice have reduced intra-adipose GC action but exaggerated CORT-mediated GC amplification
------------------------------------------------------------------------------------------------------

Corticosterone-treated *Pomc*^*−/−*^ and wild-type mice had similar plasma corticosterone levels and hypothalamic CRH mRNA levels ([@bib6]). To examine potential mechanisms of corticosterone hypersensitivity in *Pomc*^*−/−*^ mice, 11β-HSD1 and GR mRNA levels were measured in epididymal, inguinal and retroperitoneal adipose depots. Adipose 11β-HSD1 mRNA expression was lower in all untreated *Pomc*^*−/−*^ compared with wild-type mice ([Fig. 1](#fig1){ref-type="fig"}A) and was dramatically increased by corticosterone in both genotypes ([Fig. 1](#fig1){ref-type="fig"}A), with larger increases (two- to four-fold greater) in *Pomc*^*−/−*^ mice.

Adipose expression of GR mRNA was higher in the retroperitoneal fat of *Pomc*^*−/−*^ mice and restored to wild-type levels by corticosterone treatment ([Fig. 1](#fig1){ref-type="fig"}B). GR mRNA levels did not differ in inguinal and epididymal fat between *Pomc*^*−/−*^ and wild-type mice, and were unaffected by corticosterone treatment in either genotype ([Fig. 1](#fig1){ref-type="fig"}B).

To investigate mechanisms downstream of 11β-HSD1/GR by which corticosterone treatment selectively increases fat mass in *Pomc*^*−/−*^ mice, adipose levels of mRNA encoding LPL, a glucocorticoid-regulated gene ([@bib13]), were measured. Although LPL mRNA levels were the same in untreated *Pomc*^*−/−*^ and wild-type mice in all depots, adipose LPL expression in *Pomc*^*−/−*^ mice was markedly increased by corticosterone treatment ([Fig. 1](#fig1){ref-type="fig"}C) consistent with increased triglyceride uptake, and fat mass in *Pomc*^*−/−*^ mice. In wild-type mice, corticosterone treatment increased LPL mRNA only in the inguinal depot, and to a lesser extent than in *Pomc*^*−/−*^ mice ([Fig. 1](#fig1){ref-type="fig"}C), suggesting adipose depot-dependent regulation of LPL by glucocorticoids in non-obese mice, consistent with previous data in rats ([@bib12]).

PEPCK is an enzyme essential for gluconeogenesis in liver and glycerol synthesis in adipose tissue ([@bib39], [@bib43]). PEPCK is a classical glucocorticoid target gene which is positively regulated by glucocorticoids in hepatocytes and negatively regulated in adipocytes ([@bib47], [@bib35]). Consistent with this, adipose PEPCK mRNA levels were decreased in epididymal and retroperitoneal fat by corticosterone treatment in wild-type mice ([Fig. 1](#fig1){ref-type="fig"}D). Surprisingly, given their glucocorticoid deficiency, *Pomc*^*−/−*^ mice had lower levels of PEPCK mRNA in adipose tissue than in wild-type ([Fig. 1](#fig1){ref-type="fig"}D). However, although corticosterone treatment in *Pomc*^*−/−*^ mice decreased PEPCK expression in inguinal and retroperitoneal adipose tissue (significantly lower than in corticosterone-treated wild-type mice; *P*=0·01), it had no effect on PEPCK mRNA levels in epididymal adipose tissue, suggesting that other regulatory factors dominate PEPCK expression in adipose tissue of *Pomc*^*−/−*^ mice ([Fig. 1](#fig1){ref-type="fig"}D).

*Pomc*^*−/−*^ mice are dyslipidaemic, and have unaltered hepatic 11β-HSD1 but higher GR mRNA levels
---------------------------------------------------------------------------------------------------

Hepatic 11β-HSD1 mRNA levels were similar between the two genotypes ([Fig. 2](#fig2){ref-type="fig"}A) and unaffected by corticosterone ([Fig. 2](#fig2){ref-type="fig"}A). Hepatic GR mRNA levels were higher in *Pomc*^*−/−*^ compared with wild-type mice ([Fig. 2](#fig2){ref-type="fig"}B), but again corticosterone had no effect on GR mRNA levels ([Fig. 2](#fig2){ref-type="fig"}B).

Hepatic PEPCK expression was lower in *Pomc*^*−/−*^ than in wild-type mice ([Fig. 2](#fig2){ref-type="fig"}C) and was increased by corticosterone treatment to levels equivalent to untreated wild-type mice. In contrast, corticosterone decreased hepatic PEPCK mRNA levels in wild-type mice ([Fig. 2](#fig2){ref-type="fig"}C).

*Pomc*^*−/−*^ mice showed markedly higher circulating triglyceride levels ([Fig. 3](#fig3){ref-type="fig"}A) and hepatic lipid accumulation than wild-type mice ([Fig. 3](#fig3){ref-type="fig"}B), with sixfold higher levels of hepatic triglyceride (*P*\<0·001; [Fig. 3](#fig3){ref-type="fig"}C). However, corticosterone had no effect on plasma triglyceride levels in either genotype ([Fig. 3](#fig3){ref-type="fig"}A), nor did it worsen the liver phenotype ([Fig. 3](#fig3){ref-type="fig"}C). *Pomc*^*−/−*^ and wild-type mice had similar plasma NEFA levels which were unaffected by corticosterone ([Fig. 3](#fig3){ref-type="fig"}D).

CORT drives hypertension in *Pomc*^*−/−*^ mice independently of adipose and liver RAS activation
------------------------------------------------------------------------------------------------

*Pomc*^*−/−*^ mice had similar blood pressure to wild-type mice ([Fig. 4](#fig4){ref-type="fig"}A). Corticosterone markedly increased blood pressure only in *Pomc*^*−/−*^ mice ([Fig. 4](#fig4){ref-type="fig"}A). Since hypertension following transgenic expression of 11β-HSD1 in adipose or liver is associated with increased levels of angiotensinogen in each of these tissues respectively ([@bib29], [@bib37]), we hypothesised that a similar mechanism may drive corticosterone-mediated hypertension in *Pomc*^*−/−*^ mice. We therefore examined key components of the RAS ([@bib15]). *Pomc*^*−/−*^ mice had higher hepatic angiotensinogen mRNA levels than controls ([Fig. 4](#fig4){ref-type="fig"}B). However, corticosterone did not alter hepatic angiotensinogen mRNA levels in either genotype ([Fig. 4](#fig4){ref-type="fig"}B). Consistent with lower intra-adipose GC action, adipose angiotensinogen mRNA levels were lower in *Pomc*^*−/−*^ mice in all adipose depots ([Fig. 4](#fig4){ref-type="fig"}C). Corticosterone increased angiotensinogen mRNA levels specifically in epididymal adipose tissue of both genotypes (twofold increase; *P*\<0·001; [Fig. 4](#fig4){ref-type="fig"}C) but had no effect on angiotensinogen mRNA levels in inguinal or retroperitoneal adipose tissue of either genotype ([Fig. 4](#fig4){ref-type="fig"}C). Plasma angiotensinogen concentrations did not differ with genotype or corticosterone ([Fig. 4](#fig4){ref-type="fig"}D). As has been found in another model of glucocorticoid-deficient obesity ([@bib31]), plasma renin concentration was markedly higher in *Pomc*^*−/−*^ mice ([Fig. 4](#fig4){ref-type="fig"}E) but this was unaffected by corticosterone ([Fig. 4](#fig4){ref-type="fig"}E).

Discussion
==========

Increased glucocorticoid action specifically in adipose ([@bib29]) or liver ([@bib37]) produces distinct metabolic syndromes with hypertension. Increased GR sensitivity is also associated with altered fat distribution, hypertension and cardiometabolic disease ([@bib2], [@bib44], [@bib9], [@bib50],[@bib51], [@bib53]). We hypothesised that altered tissue regeneration of active glucocorticoid and/or peripheral tissue sensitivity to GCs might explain in part the exaggerated fat accumulation, insulin resistance ([@bib6]) and the hypertension observed in *Pomc*^*−/−*^ mice with glucocorticoid replacement.

With fixed circulating glucocorticoid levels, 11β-HSD1 and GR expression levels are the key determinants of GC action. *Pomc*^*−/−*^ mice had lower adipose but similar hepatic levels of 11β-HSD1 mRNA levels to wild-type mice. Corticosterone treatment dramatically and more markedly increased 11β-HSD1 in the adipose tissue of *Pomc*^*−/−*^ mice. This was accompanied by a marked increase in the expression of the glucocorticoid-inducible ([@bib13]) gene *LPL*, which is consistent with the exaggerated accumulation of fat in these mice. Intriguingly, these data suggest that, at least in adipose tissue, 11β-HSD1 itself is a glucocorticoid target gene. This finding is consistent with most ([@bib16], [@bib19], [@bib54], [@bib3]), but not all ([@bib34]) previous reports of glucocorticoid induction of 11β-HSD1 in a variety of cell types. Although not specifically measured here, increased adipose 11β-HSD1 activity is predicted to selectively amplify intra-adipose glucocorticoid concentrations, particularly when circulating levels of substrate are high. On the other hand, our data suggest that congenital glucocorticoid deficiency has little impact upon hepatic 11β-HSD1 levels *in vivo* and is not regulated by corticosterone. In contrast, 11β-HSD1 mRNA levels are highly and positively regulated by glucocorticoids in adipose tissue.

GR levels are another major determinant of cellular glucocorticoid sensitivity ([@bib52], [@bib14]). Small differences in GR mRNA levels can markedly alter glucocorticoid responsiveness ([@bib14], [@bib42]). *Pomc*^*−/−*^ mice had elevated GR mRNA levels in liver and retroperitoneal adipose tissue, suggesting increased glucocorticoid sensitivity selectively in these depots. Following corticosterone replacement in *Pomc*^*−/−*^ mice, GR mRNA levels were restored to wild-type levels in retroperitoneal adipose tissue but not in liver, consistent with tissue- and time-specific differences in GR autoregulation ([@bib21], [@bib10], [@bib48], Holmes *et al.*, [@bib18], [@bib17], [@bib42]).

Corticosterone had no additional effects on the hypertriglyceridaemia and fatty liver of the *Pomc*^*−/−*^ mice, and did not affect plasma NEFAs, which were normal in *Pomc*^*−/−*^ mice. The corticosterone-driven caloric excess in *Pomc*^*−/−*^ mice may drive a further increase in the flux of triglycerides from the liver, that, coupled with increased adipose uptake via LPL, maintains the circulating and liver triglyceride levels constant and is consistent with increased adipose tissue mass in corticosterone-treated *Pomc*^*−/−*^ mice ([@bib6]).

Adipose PEPCK is critical for glyceroneogenesis and is thus a key regulator of the level of fatty acid re-esterification (reviewed in [@bib43]). Unexpectedly, since glucocorticoids reduce adipose PEPCK, glucocorticoid-deficient *Pomc*^*−/−*^ mice had lower levels of PEPCK mRNA in all adipose depots. This was further decreased by corticosterone treatment. The lower level of PEPCK mRNA in untreated *Pomc*^*−/−*^ mice may be due to their higher fed blood glucose levels ([@bib35], [@bib36]), thus reducing the need for glyceroneogenesis to generate glycerol phosphate for fatty acid re-esterification. *Pomc*^*−/−*^ mice have lower hepatic expression of PEPCK. This may not be due to the lack of glucocorticoid signalling in liver, as mice with a liver-specific knockout of GR have normal levels of PEPCK in liver ([@bib36]), but may be related to the higher circulating levels of insulin in *Pomc*^*−/−*^ mice compared with wild-type ([@bib6]). Insulin dominantly and negatively suppresses hepatic PEPCK in the fed state ([@bib39]). In corticosterone-treated wild-type mice, the repressive effect of insulin predominated. Indeed, the decreased levels of PEPCK in these mice compared with untreated wild-type mice may reflect the increase in insulin levels following corticosterone ([@bib6]). In contrast, hepatic PEPCK mRNA levels doubled following corticosterone treatment in *Pomc*^*−/−*^ mice, consistent with hepatic insulin resistance and marked hyperinsulinaemia ([@bib6]).

Blood pressure in *Pomc*^*−/−*^ mice is normal despite their hypoadrenal state. This implies that secondary mechanisms are invoked to maintain cardiovascular function when circulating aldosterone and corticosterone concentrations are chronically reduced ([@bib5]). It seems likely that the increased renin activity which we have observed in *Pomc*^*−/−*^ mice is part of this adaptive process. However, corticosterone replacement did not normalise renin activity and selectively increased blood pressure in *Pomc*^*−/−*^ mice. This was not attributed to a further activation of the circulating RAS, since neither renin nor its substrate angiotensinogen was increased. Indeed, the expression of angiotensinogen mRNA in liver and adipose tissues did not correlate with blood pressure. It seems likely that corticosterone augmented existing mechanisms that were already sustaining vascular function. Apart from renin, these secondary processes are likely to involve the hyperinsulinaemic ([@bib49]) state of *Pomc*^*−/−*^ mice (which is exacerbated by corticosterone treatment; [@bib6]), the sympathetic nervous system ([@bib40]; which is thought to explain glucocorticoid-induced hypertension in normal mice) or structural adaptation of the vasculature ([@bib55]).

In summary, we show that increased adipose tissue-specific sensitivity to glucocorticoids in *Pomc*^*−/−*^ mice may result in part from exaggerated induction of 11β-HSD1 in adipose tissue with corticosterone administration. Whilst acknowledging that mRNA changes do not always translate to altered protein (or enzyme activity) levels, these data nevertheless suggest that 11β-HSD1 might be a more potent mediator of intra-adipose GC action than the GR levels, whereas in liver, higher GR levels contribute to the diabetogenic phenotype of the *Pomc*^*−/−*^ mice.
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![Mediators of GC action in adipose tissue of *Pomc*^*−/−*^ mice and effects of CORT treatment on GC target genes. (A) Representative northern blot showing levels of 11β-HSD1 mRNA and 18S RNA in epididymal adipose tissue of *Pomc*^*−/−*^ (−/−) and wild-type (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). (B--E) Quantitation of adipose tissue-specific 11β-HSD1 (B), GR (C), LPL (D) and PEPCK (E) mRNA levels in experimental mice. Epi, epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are presented as percentage of the value in untreated wild-type mice (100%) and are the means±[s.e.m.]{.smallcaps}; *n*=5 per group. Significance \**P*\<0·05, \*\**P*\<0·01 and \*\*\**P*\<0·001.](JOE070090f01){#fig1}

![Mediators of GC action in the liver of *Pomc*^*−/−*^ mice and effects of CORT treatment on GC target genes. Liver mRNA expression of (A) 11β-HSD1, (B) GR and (C) PEPCK in *Pomc*^*−/−*^ (−/−) and wild-type (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). Data are presented as percentages of the value in untreated control mice (100%) and are the means±[s.e.m.]{.smallcaps}; *n*=5 per group. Significance \**P*\<0·05, \*\**P*\<0·01 and \*\*\**P*\<0·001.](JOE070090f02){#fig2}

![Dyslipidaemia and fatty liver in *Pomc*^*−/−*^ mice. (A) Plasma triglyceride levels in *Pomc*^*−/−*^ (−/−) and wild-type (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). (B) Oil Red O staining of neutral lipid in liver sections of wild-type mice (+/+, left upper panel), CORT-treated wild-type mice (+/+, left bottom panel), *Pomc*^*−/−*^ (−/−, right upper panel) and CORT-treated *Pomc*^*−/−*^ (−/−, right bottom panel). Magnification is 40×; red, oil red O; blue, haematoxylin (nuclei). (C) Hepatic triglyceride content in *Pomc*^*−/−*^ (−/−) and wild-type (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). (D) Plasma levels of non-esterified fatty acids (NEFA) in *Pomc*^*−/−*^ (−/−) and wild-type (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). Data are means±[s.e.m.]{.smallcaps}; (*n*=6 per group). Significance \*\*\**P*\<0·001.](JOE070090f03){#fig3}

![Corticosterone treatment increases blood pressure in *Pomc*^*−/−*^ mice: effect of CORT treatment on the Renin-angiotensin system. Effect of 10 days corticosterone treatment (cort) on (A) systolic blood pressure, (B) renin concentration, (C) plasma angiotensinogen, (D) angiotensinogen (Agt) mRNA in adipose tissue (AT), and (E) angiotensinogen (Agt) mRNA levels in liver in wild-type (+/+) and *Pomc*^*−/−*^ (−/−) mice. Epi, epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are means±[s.e.m.]{.smallcaps}, and for transcript levels are expressed relative to levels in untreated wild-type mice (100%); *n*=5 per group. Significance \**P*\<0·05, \*\**P*\<0·01 and \*\*\**P*\<0·001.](JOE070090f04){#fig4}
